联合免疫治疗在晚期肾细胞癌一线治疗中的新兴作用:综述
本综述聚焦晚期肾细胞癌一线治疗,指出单药免疫治疗存在原发或适应性耐药。多项晚期试验正在研究双免疫检查点抑制或免疫检查点联合血管内皮生长因子抑制。纳武利尤单抗联合伊匹木单抗、阿替利珠单抗联合贝伐珠单抗的初步研究显示,在初治晚期肾细胞癌患者中疗效优于苹果酸舒尼替尼,且安全性特征与舒尼替尼相比更有利。免疫检查点抑制与独特的免疫相关不良事件相关,临床医生需掌握识别与管理方法。结论认为,基于免疫治疗的联合方案将成为晚期肾细胞癌一线及后线治疗的重要补充,优化免疫相关不良事件管理对最大化疗效至关重要。
要点
- 纳武利尤单抗联合伊匹木单抗、阿替利珠单抗联合贝伐珠单抗在初治晚期肾细胞癌中初步显示优于苹果酸舒尼替尼的疗效,安全性特征也更有利。
- 单药免疫检查点抑制存在原发或适应性耐药,联合策略旨在拓宽获益人群而不加重毒性。
- 免疫检查点抑制伴随独特的免疫相关不良事件,临床医生需接受识别与管理培训。
核心结论
- 证据提示,基于免疫治疗的联合方案将成为晚期肾细胞癌一线及后线治疗的重要补充。
- 临床研究数据与实践经验表明,优化免疫相关不良事件的管理对最大化这些治疗的获益至关重要。
研究设计与样本
- 本综述汇总了晚期肾细胞癌免疫联合治疗的相关研究,包括正在进行的多项晚期试验,涉及双免疫检查点抑制或免疫检查点联合血管内皮生长因子抑制。
主要发现
- 纳武利尤单抗联合伊匹木单抗、阿替利珠单抗联合贝伐珠单抗的初步研究显示,在初治晚期肾细胞癌患者中疗效优于苹果酸舒尼替尼。
- 上述联合方案的安全性特征与苹果酸舒尼替尼相比更有利。
- 单药免疫治疗可观察到原发或适应性耐药。
- 免疫检查点抑制与独特的免疫相关不良事件相关。
临床怎么用
- 临床医生需接受教育,以最佳方式识别和管理免疫检查点抑制相关的免疫相关不良事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Novel immunotherapies, notably the immune checkpoint inhibitors, have been shown to be efficacious in patients with advanced renal cell carcinoma, but innate or adaptive resistance is observed with single-agent immunotherapy. New combination treatment strategies are needed that can improve efficacy in a broader patient population, without exacerbating the toxic effects. OBSERVATIONS: Numerous late-phase trials are ongoing to investigate (1) dual immune checkpoint inhibition or (2) combined inhibition of immune checkpoints and vascular endothelial growth factor. Initial results from studies of the nivolumab plus ipilimumab and atezolizumab plus bevacizumab combinations have demonstrated efficacy compared with sunitinib malate in treatment-naïve patients with advanced renal cell carcinoma; moreover, the safety profile of these combinations compare favorably with sunitinib. Nevertheless, immune checkpoint inhibition is associated with unique immune-related adverse events, and practicing physicians must be educated on how to best identify and manage these events. CONCLUSIONS AND RELEVANCE: Evidence suggests that immunotherapy-based combination regimens will be an important addition to the treatment of advanced renal cell carcinoma in both the first- and later-line setting; however, clinical study data and clinical practice experience indicate that optimizing the management of the associated immune-related adverse events is essential to maximizing the advantages of these therapies.
引用
- George S, Rini BI, Hammers HJ, et al. Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review. JAMA Oncol. 2019. PMID: 30476955. doi:10.1001/jamaoncol.2018.4604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。